



Office of the Vermont Attorney
General 109 State Street
Montpelier, VT 05609

Re: New High-Cost Prescription Drugs Reporting

Dear Office of the Vermont Attorney General,

In compliance with 18 V.S.A. § 4637(b), Kadmon Pharmaceuticals LLC ("Kadmon") hereby provides to the State of Vermont new drug notices for REZUROCK™.

- (1) The NDC shall be reported in numeric form;
 - 79802-200-30
- (2) FDA approval received on July 16, 2021, and commercial product expected to be available in August, 2021;
- (3) The wholesale acquisition cost of the new prescription drug as of the introduction to market date;
 - \$15,500.00

If you have any further questions, please do not hesitate to contact me.

Regards,

A handwritten signature in black ink, appearing to read "G. Moss", written over a circular stamp or seal.

Gregory S. Moss
EVP, General Counsel and Corporate Secretary
Chief Compliance Officer